Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin

Por Giovannetti, E, Zucali, P A, Assaraf, Y G, Leon, L G, Smid, K, Alecci, C, Giancola, F, Destro, A, Gianoncelli, L, Lorenzi, E, Roncalli, M, Santoro, A, Peters, G J
Publicado em 2011

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma

Por Ceresoli, G L, Zucali, P A, Mencoboni, M, Botta, M, Grossi, F, Cortinovis, D, Zilembo, N, Ripa, C, Tiseo, M, Favaretto, A G, Soto-Parra, H, De Vincenzo, F, Bruzzone, A, Lorenzi, E, Gianoncelli, L, Ercoli, B, Giordano, L, Santoro, A
Publicado em 2013